Goldman Sachs
PRME icon

Goldman Sachs’s Prime Medicine PRME Stock Holding History

Goldman Sachs’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.38M Sell
970,425
-785,343
-45% -$2.99M ﹤0.01% 4072
2025
Q4 		$6.09M Buy
1,755,768
+1,345,032
+327% +$5.98M ﹤0.01% 3561
2025
Q3 		$2.28M Buy
410,736
+203,728
+98% +$828K ﹤0.01% 4360
2025
Q2 		$511K Sell
207,008
-44,391
-18% -$68.4K ﹤0.01% 5146
2025
Q1 		$500K Sell
251,399
-170,499
-40% -$435K ﹤0.01% 5180
2024
Q4 		$1.23M Buy
421,898
+201,754
+92% +$708K ﹤0.01% 4667
2024
Q3 		$852K Buy
220,144
+140,777
+177% +$652K ﹤0.01% 4747
2024
Q2 		$408K Buy
79,367
+41,187
+108% +$250K ﹤0.01% 4932
2024
Q1 		$267K Sell
38,180
-12,969
-25% -$98.4K ﹤0.01% 5018
2023
Q4 		$453K Sell
51,149
-7,762
-13% -$59.8K ﹤0.01% 4816
2023
Q3 		$562K Buy
+58,911
New +$765K ﹤0.01% 4606

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Goldman Sachs's PRME Position: Q1 2026 in Review

Goldman Sachs reduced its Prime Medicine (PRME) stake by 45% in Q1 2026, selling an estimated $2.99M and leaving 970,425 shares worth $3.38M. The position accounts for ﹤0.01% of the portfolio, ranked #4072.

Goldman Sachs first reported a position in PRME in Q3 2023 and has held it in 11 quarters since. The position peaked at $6.09M in Q4 2025. 192 funds tracked by Wall St. Rank hold PRME as of Q1 2026.

  • Goldman Sachs held 970,425 shares of Prime Medicine worth $3.38M as of Q1 2026.
  • Goldman Sachs sold 785,343 Prime Medicine shares in Q1 2026, an estimated $2.99M.
  • Prime Medicine made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #4072 holding.
  • Goldman Sachs first reported a position in Prime Medicine in Q3 2023 and has held it in 11 quarters since.
  • Goldman Sachs's Prime Medicine position peaked at $6.09M in Q4 2025.
  • 192 funds tracked by Wall St. Rank held Prime Medicine as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.